Momentum 3 Trial - 5-Year Data | Abbott
CARDIOVASCULAR
hamburger

Momentum 3 5-Year Outcomes

This study examines outcomes from the 5-year extended analysis of the MOMENTUM 3 trial, comparing HeartMate 3™ LVAD to HeartMate II™ LVAD

5-year Survival with LVAD Therapy in MOMENTUM 3

Mehra, MR. 5-Year Survival with LVAD Therapy in MOMENTUM 3. Presented at: European Society of Cardiology (ESC) Annual Meeting; August 28, 2022; Barcelona, Spain.

This extension of the MOMENTUM 3 study extended out 5 years and showed the superior treatment effect of the HeartMate 3 LVAD over HeartMate II LVAD on HRAEs, which was associated with improved survival at 5-years:

  • Improved survival was driven by a reduction in hemocompatibility-related deaths, e.g. thrombosis, stroke, and bleeding
  • This study demonstrates that median survival with the HM3 reliably exceeds 5 years, even in those patients with refractory heart failure who are ineligible for transplantation

MAT-2210315 v2.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.